SelankCheck methods and identity
What the Early Selank Comparisons Measured About Anxiety
2 numbered sourcesSource years 2008, 2014
Peptides are short chains of amino acids linked by peptide bonds. Some can influence signaling pathways that researchers study in relation to behavior. Selank is a synthetic seven-amino-acid peptide modeled on a peptide called tuftsin. It has been investigated in anxiety research. The direct clinical comparisons described here are older: a search of recent indexed articles did not identify a newer original trial that answered the same question. [1, 2]
In one report, Zozulia and colleagues studied 62 patients with generalized anxiety disorder or neurasthenia. They compared Selank with the active comparator medazepam and used symptom scales. The authors described similar changes in anxiety on those measures. In another report, Medvedev and colleagues compared Selank with phenazepam in a group of 60 people with several types of anxiety-related and somatoform disorders. That report also described favorable changes on some measures. The public abstracts provide limited information about the methods needed to judge the comparisons. [1, 2]
An active comparison can be useful, but two groups showing a similar change is not the same as demonstrating equivalent effects. Equivalence requires a study designed to rule out a difference larger than a specified amount. A placebo comparison can answer a different question about improvement beyond expectations, time and other aspects of care. The reports also involved selected groups and different diagnoses, which limits how readily they can be combined. [1, 2]
The studies show what researchers tried to measure: changes in symptom scales and aspects of functioning. They do not establish how consistently Selank works in a larger population, how it compares with contemporary approaches to care, or what its long-term safety is.
Sources
Original works cited in this article. Links open the external record in a new tab.
